Rapamycin and mTOR: a serendipitous discovery and implications for breast cancer

TOR Signaling in Growth and Metabolism

2006 • 5,643 citations

Upstream and downstream of mTOR

2004 • 4,085 citations

mTOR: from growth signal integration to cancer, diabetes and ageing

2010 • 3,777 citations

Targets for Cell Cycle Arrest by the Immunosuppressant Rapamycin in Yeast

1991 • 1,937 citations

TOR, a Central Controller of Cell Growth

2000 • 1,919 citations

PI3K pathway alterations in cancer: variations on a theme

2008 • 1,752 citations

Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle.

1975 • 1,605 citations

Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression

2004 • 1,226 citations

Biological determinants of endocrine resistance in breast cancer

2009 • 1,206 citations

Rapamycin-FKBP specifically blocks growth-dependent activation of and signaling by the 70 kd S6 protein kinases

1992 • 1,146 citations

Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E

2002 • 1,064 citations

Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study

2011 • 1,004 citations

Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization.

1975 • 908 citations

Randomized Phase II Trial of Everolimus in Combination With Tamoxifen in Patients With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer With Prior Exposure to Aromatase Inhibitors: A GINECO Study

2012 • 674 citations

IMMUNOPHARMACOLOGY OF RAPAMYCIN

1996 • 651 citations

Regulation of cellular growth by the Drosophila target of rapamycin dTOR

2000 • 615 citations

Expression and disruption of the Arabidopsis TOR (target of rapamycin) gene

2002 • 450 citations

Targeting mTOR signaling for cancer therapy

2003 • 439 citations

Genetic and biochemical characterization of dTOR, the Drosophila homolog of the target of rapamycin

2000 • 431 citations

Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer

2011 • 427 citations

Inhibition of mTOR Activity Restores Tamoxifen Response in Breast Cancer Cells with Aberrant Akt Activity

2004 • 381 citations

Signaling by Target of Rapamycin Proteins in Cell Growth Control

2005 • 330 citations

A role of the kinase mTOR in cellular transformation induced by the oncoproteins P3k and Akt

2000 • 296 citations

TOR Deficiency in C. elegans Causes Developmental Arrest and Intestinal Atrophy by Inhibition of mRNA Translation

2002 • 271 citations

Role of mTOR in anticancer drug resistance: Perspectives for improved drug treatment

2008 • 234 citations

Phase I Study of Everolimus Plus Weekly Paclitaxel and Trastuzumab in Patients With Metastatic Breast Cancer Pretreated With Trastuzumab

2010 • 209 citations

Phase I/II Study of Trastuzumab in Combination With Everolimus (RAD001) in Patients With HER2-Overexpressing Metastatic Breast Cancer Who Progressed on Trastuzumab-Based Therapy

2011 • 207 citations

New antitumor substances of natural origin

1981 • 197 citations

Will mTOR inhibitors make it as cancer drugs?

2003 • 193 citations

Integration of Growth Factor and Nutrient Signaling

2003 • 187 citations

The p70 S6 Kinase Integrates Nutrient and Growth Signals to Control Translational Capacity

2001 • 180 citations

Rapamycin Antifungal Action Is Mediated via Conserved Complexes with FKBP12 and TOR Kinase Homologs inCryptococcus neoformans

1999 • 164 citations

The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer: Results of a phase I study with pharmacokinetics

2007 • 153 citations

Identification of TOR Signaling Complexes

2002 • 149 citations

Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer

2010 • 140 citations

The mammalian target of the rapamycin (mTOR) kinase pathway: its role in tumourigenesis and targeted antitumour therapy.

2005 • 104 citations

Network-level molecular evolutionary analysis of the insulin/TOR signal transduction pathway across 12 Drosophila genomes

2009 • 88 citations

Adaptive hypersensitivity to estrogen: Mechanisms and clinical relevance to aromatase inhibitor therapy in breast cancer treatment

2005 • 81 citations

Rapamycin's Resurrection: A New Way to Target the Cancer Cell Cycle

2001 • 81 citations

A role of the kinase mTOR in cellular transformation induced by the oncoproteins P3k and Akt

2000 • 63 citations

An Evolving Role for DEPTOR in Tumor Development and Progression

2012 • 60 citations

“Overcoming breast cancer drug resistance with mTOR inhibitors”. Could it be a myth or a real possibility in the short-term future?

2010 • 56 citations

Mammalian Target of Rapamycin Inhibitors in Combination with Letrozole in Breast Cancer

2006 • 48 citations

Novel therapeutic strategies combining antihormonal and biological targeted therapies in breast cancer: Focus on clinical trials and perspectives

2007 • 34 citations

Everolimus: Targeted Therapy on the Horizon for the Treatment of Breast Cancer

2012 • 31 citations

Dedicated breast computed tomography: Volume image denoising via a partial‐diffusion equation based technique

2008 • 29 citations

Decline in Breast Cancer Incidence--United States, 1999-2003

2007 • 25 citations